List of Nucynta drug patents

Nucynta is owned by Collegium Pharm Inc.

Nucynta contains Tapentadol Hydrochloride.

Nucynta has a total of 2 drug patents out of which 1 drug patent has expired.

Expired drug patents of Nucynta are:

  • USRE39593

Nucynta was authorised for market use on 15 October, 2012.

Nucynta is available in solution;oral dosage forms.

Nucynta can be used as relief of moderate to severe acute pain.

The generics of Nucynta are possible to be released after 27 June, 2025.

NUCYNTA Litigations
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
USRE39593 COLLEGIUM PHARM INC 1-phenyl-3-dimethylaminopropane compounds with a pharmacological effects
Aug, 2022

(7 months ago)

US7994364 COLLEGIUM PHARM INC Crystalline forms of (−)-(1R,2R)-3-(3-dimethylamino-1-ethyl-2-methylpropyl)-phenol hydrochloride
Jun, 2025

(2 years from now)

Drugs and Companies using TAPENTADOL HYDROCHLORIDE ingredient

Market Authorisation Date: 15 October, 2012

Treatment: Relief of moderate to severe acute pain

Dosage: SOLUTION;ORAL

How can I launch a generic of NUCYNTA before it's patent expiration?
More Information on Dosage

NUCYNTA family patents

15

United States

3

Norway

3

European Union

2

Portugal

2

Germany

2

Spain

2

Brazil

2

Argentina

2

Austria

2

Cyprus

2

Slovenia

2

Poland

2

Denmark

1

Russia

1

Croatia

1

New Zealand

1

Mexico

1

Peru

1

China

1

Korea, Republic of

1

South Africa

1

Canada

1

Japan

1

Israel

1

Australia

1

Ecuador

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic